Westcott, Peter MK, Muyas, Francesc, Hauck, Haley, Smith, Olivia C, Sacks, Nathan J, Ely, Zackery A, Jaeger, Alex M, Rideout, William M, Zhang, Daniel, Bhutkar, Arjun, Beytagh, Mary C, Canner, David A, Jaramillo, Grissel C, Bronson, Roderick T, Naranjo, Santiago, Jin, Abbey, Patten, JJ, Cruz, Amanda M, Shanahan, Sean-Luc, Cortes-Ciriano, Isidro, Jacks, Tyler (September 2023) Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nature Genetics. ISSN 1061-4036
Preview |
PDF
2023_Westcott_Mismatch_Repair_Deficiency_Is_Not_Sufficient.pdf - Published Version Available under License Creative Commons Attribution. Download (19MB) | Preview |
Abstract
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden (TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most MMRd tumors do not durably respond to ICB and critical questions remain about immunosurveillance and TMB in these tumors. In the present study, we developed autochthonous mouse models of MMRd lung and colon cancer. Surprisingly, these models did not display increased T cell infiltration or ICB response, which we showed to be the result of substantial intratumor heterogeneity of mutations. Furthermore, we found that immunosurveillance shapes the clonal architecture but not the overall burden of neoantigens, and T cell responses against subclonal neoantigens are blunted. Finally, we showed that clonal, but not subclonal, neoantigen burden predicts ICB response in clinical trials of MMRd gastric and colorectal cancer. These results provide important context for understanding immune evasion in cancers with a high TMB and have major implications for therapies aimed at increasing TMB.
Actions (login required)
 |
Administrator's edit/view item |